Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer
Recombinant granulocyte colony-stimulating factor (G-CSF) [filgrastim and lenograstim] and pegylated G-CSF (pegfilgrastim) have been shown to reduce the severity and duration of chemotherapy-associated febrile neutropenia (FN) when administered prophylactically to cancer patients receiving chemotherapeutic regimens. The American Society of Clinical Oncology (ASCO) evidence-based clinical guidelines published in 1994, 1996 and 1997 recommended primary prophylaxis with G-CSF for cancer patients. The 2000 ASCO update, with the same recommendation, highlights the importance of economic considerations in decision making for CSFs. This paper reviews the available cost-effectiveness evidence on the use of G-CSF as primary prophylaxis against FN in patients with small cell lung cancer (SCLC).
Cost-effectiveness ratios from a healthcare payer perspective supported the use of filgrastim as primary prophylaxis for people with SCLC, on the basis of both clinical and economic benefits, treated with chemotherapeutic regimens that have an FN rate in the range of 40–60%. However, when indirect and patient out-of-pocket costs attributable to severe FN are included, available evidence suggests that the risk threshold may be reduced by more than half.
Given that FN rates associated with chemotherapeutic regimens for SCLC are generally <40%, then few circumstances would warrant the use of G-CSFs (filgrastim and lenograstim) under the current rule. However, inclusion of indirect costs would lower the cost-effectiveness threshold. Future cost-effectiveness studies of medications such as pegfilgrastim should attempt to capture the societal perspective by incorporating productivity-related costs and using base-case rates of FN reported in the literature.
KeywordsSmall Cell Lung Cancer Febrile Neutropenia National Comprehensive Cancer Network Filgrastim Direct Medical Cost
Drs Calhoun and Bennett have received unrestricted grants and consultancy fees from Amgen.
- 1.Abeloff MD, Armitage JO, Niederhuber JE, et al. Clinical Oncology. 3rd ed. Philadelphia (PA): Elsevier Churchill Livingstone, 2004Google Scholar
- 3.Holmes FA, O’shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–31PubMedCrossRefGoogle Scholar
- 5.ASCO CSF Guideline Expert Panel. Update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957–60Google Scholar
- 6.2000 update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000 Oct; 18 (20): 3558–85Google Scholar
- 13.US Dept of Labor, Bureau of Labor Statistics [online]. Available from URL: http://www.bls.gov/opub/ted/2002/may/wk3/art04.txt [Accessed 2003 Oct 14]Google Scholar
- 14.Heckinger E, Lee J, Calhoun E, et al. Cost-minimization analysis of pegylated filgrastim (pegylated G-CSF) for stage II-IV breast cancer patients receiving chemotherapy: assessment based on third party and societal perspectives. Proc Am Soc Clin Oncol 2003, 2116aGoogle Scholar
- 17.American Cancer Society. Cancer Facts and Figures. Atlanta (GA), 2003Google Scholar
- 18.Use of hematopoietic colony-stimulating factors: evidencebased, practice guidelines. J Clin Oncol 1994; 12: 2471–508Google Scholar
- 19.Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996 Jun; 14 (6: 1957–60Google Scholar
- 20.1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1997 Oct; 15 (10): 3288Google Scholar
- 21.American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000 Oct 15; 18 (20): 3558–85Google Scholar
- 23.Bennett CL, Bishop MR, Tallman MS, et al. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Ann Oncol 1999 Nov; 10 (11): 1355–9PubMedCrossRefGoogle Scholar
- 25.Myeloid growth factors in cancer treatment [online]. Available from URL: http://neen.org/professionals/physician GLSIPDF/myeloid.growth.pdf [Accessed 2005 Jun 27]Google Scholar
- 29.Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996Google Scholar